CAR-NK Cells (CL-NK-001) in Pancreatic Cancer

This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.

Trial Details

NCT ID
NCT06816823
Phase
PHASE1
Sponsor
Changhai Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • CL-NK-001
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Aged 18-70 years;
  • Locally advanced, metastatic, or recurrent pancreatic cancer, with immunohistochemical detection of eGR1 (membrane positive tumor cell rate \>40% a…
  • At least 1 measurable lesion according to RECIST 1.1;
  • Have not received anti-tumor treatment for at least 4 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →